• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Odyssey Health Inc (OP:ODYY)

    0.0060 -0.0004 (-6.25%)
    Streaming Delayed Price Updated: 12:53 PM EDT, Jul 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Odyssey Health Inc

    < Previous 1 2 3 Next >
    Researchers Develop AI Tool That Scans Retina, Detects Heart Disease in One Minute
    Via Investor Brand Network
    Topics Artificial Intelligence
    Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate
    Via Investor Brand Network
    BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Formation of Subsidiary Focused on Treating Neurological Disorders
    Via Investor Brand Network
    Topics Intellectual Property
    Helmets Will Not Protect Individuals Against Concussions, Expert Says
    Via Investor Brand Network
    New Study Finds Hypertension Accelerates Bone Aging
    Via Investor Brand Network
    Ways to Prevent a Child from Choking
    Via Investor Brand Network
    Research to Examine Potential Link Between Concussions, Long COVID
    Via Investor Brand Network
    Odyssey Health, Inc. (ODYY) PRV-002 Compound Takes on Heightened Significance Following Recent Concussion of Dolphins Quarterback Tua Tagovailoa, and the NFL and NFLPA’s Announcement on Changes to Concussion Protocol
    Via Investor Brand Network
    BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Issues Recap of Concussion Drug Development Program
    Via Investor Brand Network
    Topics Intellectual Property
    Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated
    Via Investor Brand Network
    Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial
    Via Investor Brand Network
    InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Dissolves Sports Board, Releases Statement on Drug-Development Program
    Via Investor Brand Network
    Topics Intellectual Property
    BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Clinical Trial for PRV-002
    Via Investor Brand Network
    Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs
    Via Investor Brand Network
    NFL Reveals That Players Wearing Guardian Caps Reduced Concussion Rates by More than 50%
    Via Investor Brand Network
    Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses
    Via Investor Brand Network
    BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Eyes Intranasal Brain Targeting as Key to Success of PRV-002
    Via Investor Brand Network
    Topics Intellectual Property
    BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Reports Successful Safety Outcomes for Most Recent Phase of Concussion Drug Trial
    Via Investor Brand Network
    Study Finds That Using Headgear May Reduce Concussion Risk in Lacrosse Players
    Via Investor Brand Network
    Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage
    Via Investor Brand Network
    BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in NeurologyLive(R) Article
    Via Investor Brand Network
    Topics Intellectual Property
    BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Poised to Offer First-of-Its-Kind Responsiveness to Concussion
    Via Investor Brand Network
    Topics Intellectual Property
    Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product
    Via Investor Brand Network
    Report Details Most Prevalent Symptoms of Six Cardiovascular Illnesses
    Via Investor Brand Network
    Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate
    Via Investor Brand Network
    BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
    Via Investor Brand Network
    BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured on ‘Dr. Finance Live’ Podcast
    Via Investor Brand Network
    Topics Intellectual Property
    BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Shares Favre Interview
    Via Investor Brand Network
    Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy
    Via Investor Brand Network
    Topics Animal Testing
    BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from MAD Arm of Phase I Trial
    Via Investor Brand Network
    Topics Intellectual Property
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.